scholarly journals Drug-Coated Balloon and In-Stent Restenosis: A Clinical Strategy to Manage Coronary Artery Diseases

2021 ◽  
Author(s):  
Prima Hapsari Wulandari
Keyword(s):  
Coronary Artery ◽  
Management Strategies ◽  
Coronary Intervention ◽  
Myocardial Infarctions ◽  
Coronary Artery Diseases ◽  
Stent Restenosis ◽  
Effective Interventions ◽  
Drug Coated Balloon ◽  
In Stent Restenosis ◽  
Clinical Strategy

Cardiovascular events are the most common cause of morbidity and mortality worldwide. Coronary artery diseases, including myocardial infarctions, are prevalent among all populations. There are multiple management strategies for coronary artery diseases, but stent implantation is among the most effective interventions. Nevertheless, some patients develop restenosis of the intervened vessel, and the number constitutes about 10%-20% of all patients. In-stent restenosis leads to adverse effects that might end in sudden cardiac death. Restenosis forges a clinical challenge for practicing physicians. A drug-coated balloon has propitious potential and is showing results comparable to stents implantation to overcome in-stent restenosis. This review aims to evaluate the effectiveness and advancement of drug-coated balloons in treating in-stent restenosis as a coronary intervention, along with its benefits and drawbacks.

scholarly journals Health Care Monitoring and Treatment for Coronary Artery Diseases: Challenges and Issues

Sensors ◽  
2020 ◽  
Vol 20 (15) ◽  
pp. 4303
Author(s):  
Mokhalad Alghrairi ◽  
Nasri Sulaiman ◽  
Saad Mutashar
Keyword(s):  
Coronary Artery ◽  
Blood Clotting ◽  
Coronary Artery Diseases ◽  
Monitoring Technology ◽  
Stent Restenosis ◽  
Increased Risk ◽  
Cause Of Deaths ◽  
One Year ◽  
Health Care Monitoring ◽  
In Stent Restenosis

In-stent restenosis concerning the coronary artery refers to the blood clotting-caused re-narrowing of the blocked section of the artery, which is opened using a stent. The failure rate for stents is in the range of 10% to 15%, where they do not remain open, thereby leading to about 40% of the patients with stent implantations requiring repeat procedure within one year, despite increased risk factors and the administration of expensive medicines. Hence, today stent restenosis is a significant cause of deaths globally. Monitoring and treatment matter a lot when it comes to early diagnosis and treatment. A review of the present stent monitoring technology as well as the practical treatment for addressing stent restenosis was conducted. The problems and challenges associated with current stent monitoring technology were illustrated, along with its typical applications. Brief suggestions were given and the progress of stent implants was discussed. It was revealed that prime requisites are needed to achieve good quality implanted stent devices in terms of their size, reliability, etc. This review would positively prompt researchers to augment their efforts towards the expansion of healthcare systems. Lastly, the challenges and concerns associated with nurturing a healthcare system were deliberated with meaningful evaluations.

scholarly journals Short-Term and Long-Term Efficacy of Drug-Coated Balloon for In-Stent Restenosis in Hemodialysis Patients with Coronary Artery Disease

2019 ◽  
Vol 60 (5) ◽  
pp. 1070-1076 ◽  
Author(s):  
Hiroyuki Kiriyama ◽  
Satoshi Kodera ◽  
Shun Minatsuki ◽  
Hidehiro Kaneko ◽  
Hironobu Kikuchi ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Hemodialysis Patients ◽  
Short Term ◽  
Term Efficacy ◽  
Stent Restenosis ◽  
Artery Disease ◽  
Drug Coated Balloon ◽  
In Stent Restenosis

scholarly journals Association of G22A variant of Adenosine Deaminase gene (ADA) with coronary-in-stent restenosis in coronary artery patients receiving drug-eluting stent: Short Communication

2020 ◽  
pp. 385-391
Keyword(s):  
Coronary Artery ◽  
Adenosine Deaminase ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
Stent Restenosis ◽  
Atherosclerotic Stenosis ◽  
Pcr Rflp ◽  
Drug Eluting ◽  
And Control ◽  
In Stent Restenosis

The main problem with using stents in the treatment of coronary artery atherosclerotic stenosis in percutaneous coronary intervention (PCI) is In-stent restenosis (ISR). In this study, we investigated the possible role of the G22A variant of the Adenosine Deaminase gene (ADA) in the development of ISR. In this study, 91 patients who underwent PCI were divided into two groups: the case with ISR (n=40) and control without ISR after 6 months from stenting (n=51). The case and control groups were matched in terms of age and sex matching. The genotypes of the G22A variant in the samples were examined by the molecular method of PCR-RFLP and electrophoresis and the results were statistically analyzed by using t-test. The results of this study show that the frequency of allele A of variant G22A in (+ ISR) group is higher than (- ISR). However, there is no significant relationship between the distribution of allele and genotype frequency of this variant with the incidence of ISR (p>0.05).

scholarly journals IN STENT RESTENOSIS (ISR) IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR CORONARY ARTERY DISEASE (CAD)

2021 ◽  
Vol 70 (Suppl-4) ◽  
pp. S865-70
Author(s):  
Waseem Raja ◽  
Naseer Ahmed Samore ◽  
Mohsin Saif ◽  
Javeria Kamran ◽  
Sidra Waheed ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Coronary Intervention ◽  
Vessel Coronary Artery Disease ◽  
Stent Restenosis ◽  
Percutaneous Coronary ◽  
Artery Disease ◽  
In Stent Restenosis ◽  
Vessel Coronary Artery

Objective: To study the frequency of In-Stent Restenosis and its treatment in patients undergoing Percutaneous Coronary Intervention for coronary artery disease. Study Design: Descriptive cross sectional study. Place and Duration of Study: Department of Cardiology, Armed Forces Institute of Cardiology & National Institute of Heart disease (AFIC/NIHD) Rawalpindi, from Jul 2017 to Jul 2019. Methodology: All the patients who underwent Percutaneous Coronary Intervention for Coronary Artery Disease at our institute were considered for this study. A consecutive sampling method was used and inclusion/exclusion criteria was applied. Following data was obtained; 1) Demographic information and clinical risk factors like history of hypertension, hyperlipidemia, diabetes mellitus, smoking, coronary artery disease characteristics(number of diseased arteries, bifurcation lesions, calcification, chronic total occlusions-CTO and tortuosity) 3), Stent factors (under expansion, fracture, longitudinal miss, stent gap). Data recording, storage, assessment and analysis was done by using SPSS software version 21. Results: Among 1332 cases, 50 had In-Stent Restenosis with overall prevalence of 3.75%. Mean age of the patients with In-Stent Restenosis was 58.76 (± 9.97), with 45 (90%) male and 5 (10%) female. Diabetes Mellitus was the commonest risk factor (22.9%) followed by Hypertension (18%). Sixty four percent of the patients (n=32) had Single Vessel Coronary Artery Disease, 14 (28%) had Double Vessel Coronary Artery Disease and 4 (8%) had Tripple Vessel Coronary Artery Disease. Left Anterior Descending was the commonest coronary artery that developed In-Stent Restenosis, followed by Right Coronary Artery and Left Circumflex respectively. Previously deployed stents which developed In-Stent Restenosis showed longitudinal geographical miss in 16%, stent under expansion in 6% and stent gap in 4%. There was statistically significant association (p-value=0.02) between stent length and frequency of In-Stent Restenosis and it was commonest in stents longer than 30 mm. Eighty six percent(n=43) of In-Stent Restenosis cases in our study group was treated with Drug Eluting Stent followed by Drug Eluting Balloon in 32% and Plain Old Balloon Angioplasty in 22%. Conclusion: History of diabetes mellitus and greater stent length were major risk factors in developing In-Stent Restenosis in our study. DES was the commonest treatment modality used.Keywords: , , .

Sign in / Sign up

Export Citation Format

Share Document